



**SUSCEPTIBILITY
PATTERNS OF
COMMON ISOLATES**

University of Toledo Medical Center

Jan 201%– December 201%

% SUSCEPTIBILITY OF COMMON GRAM NEGATIVE ISOLATES

Urinary and Non-Urinary All Inpatient

January 2011 - December 2011

Organism	Total # tested	Aztreonam	Amikacin	Gentamicin	Tobramycin	Ampicillin	Amp/Sulbactam	Piperacillin/Tazobactam	Imipenem/Meropenem	Cefazolin	Cefepime	Ceftriaxone	Ciprofloxacin	TMX/SMX	%ESBL positive
<i>Acinetobacter baumannii</i>	43			47%	77%		56%		49%		21%		32%		
<i>Enterobacter cloacae</i>	99	77%	99%	94%	91%				98%		95%	82%	88%	90%	
<i>Enterobacter aerogenes</i>	27*	80%	100%	92%	92%				99%		100%	86%	88%	92%	
<i>Escherichia coli</i>	773	93%	100%	90%	90%	44%	57%	90%	100%	88%	95%	93%	69%	75%	5%
<i>Klebsiella pneumoniae</i>	275	86%	99%	90%	89%		78%	78%	99%	84%	87%	87%	86%	82%	13%
<i>Proteus mirabilis</i>	195	89%	100%	65%	84%	86%	90%	99%	100%	85%	88%	88%	46%	55%	
<i>Pseudomonas aeruginosa</i>	220	57%	95%	74%	88%			76%	83%		82%		64%		

* - number is lower than CLSI recommended number of isolates to be reported (30); to be interpreted with caution

ESBL - Extended Spectrum Beta-Lactamase

% SUSCEPTIBILITY OF COMMON GRAM POSITIVE ISOLATES

Urinary and Non-Urinary All Inpatient

January 2011 - December 2011

Organism	TOTAL # TESTED	Ampicillin	Benzylpenicillin	Ceftriaxone	Clindamycin	Gentamicin	Linezolid	Oxacillin	Rifampicin	Tetracycline	Trimethoprim/Sulfamethoxazole	Vancomycin
Staphylococcus aureus (MSSA AND MRSA)	537		5%		63%	96%	100%	45%	100%	93%	92%	100%
MRSA	294				54%	95%	100%		99%	92%	89%	100%
Coagulase-negative Staphylococcus	335		3%		51%	80%	100%	34%	99%	80%	64%	100%
Enterococcus faecalis	269	94%	94%				94%			25%		96%
Enterococcus faecium	87	15%	12%				92%			11%		25%
Streptococcus pneumoniae	22*		100%	100%			100%			100%		100%

* - number is lower than CLSI recommended number of isolates to be reported (30); to be interpreted with caution

% SUSCEPTIBILITY OF COMMON GRAM NEGATIVE ISOLATES

Urinary and Non-Urinary Critical Care (SICU + MICU)

January 2011 - December 2011

Organism	Total # tested	Aztreonam	Amikacin	Gentamicin	Tobramycin	Ampicillin	Amp/Sulbactam	Piperacillin/Tazobactam	Imipenem/Meropenem	Cefazolin	Cefepime	Ceftriaxone	Ciprofloxacin	TMX/SMX	%ESBL positive
Acinetobacter baumannii	14*			21%	86%		36%		36%		7%		21%		
Enterobacter cloacae	18*	57%	100%	94%	89%				94%		100%	78%	83%	83%	
Enterobacter aerogenes	7*	57%	100%	100%	100%				100%		100%	57%	86%	100%	
Escherichia coli	70	84%	100%	85%	84%	32%	43%	89%	100%	79%	88%	88%	49%	63%	12%
Klebsiella pneumoniae	51	80%	100%	90%	82%		72%	77%	98%	82%	84%	82%	82%	82%	16%
Proteus mirabilis	31	89%	100%	65%	85%	90%	95%	100%	100%	85%	90%	90%	55%	60%	
Pseudomonas aeruginosa	48	49%	89%	65%	78%			70%	67%		74%		52%		

* - number is lower than CLSI recommended number of isolates to be reported (30); to be interpreted with caution

ESBL - Extended Spectrum Beta-Lactamase

% SUSCEPTIBILITY OF COMMON GRAM POSITIVE ISOLATES

Urinary and Non-urinary
Critical Care (SICU + MICU)
January 2011 - December 2011

Organism	TOTAL # TESTED	Ampicillin	Benzylopenicillin	Ceftriaxone	Clindamycin	Gentamicin	Linezolid	Oxacillin	Rifampicin	Tetracycline	Trimethoprim/Sulfamethoxazole	Vancomycin
Staphylococcus aureus (MSSA AND MRSA)	80				56%	97%	100%	47%	97%	94%	94%	100%
MRSA	48				38%	98%	100%		98%	90%	85%	100%
Coagulase-negative Staphylococcus	37				46%	59%	92%	26%	92%	72%	49%	92%
Enterococcus faecalis	43	95%	95%				93%			14%		95%
Enterococcus faecium	17*	6%	6%				94%			6%		24%
Streptococcus pneumoniae	8*		100%	100%			100%			88%		100%

* - number is lower than CLSI recommended number of isolates to be reported (30); to be interpreted with caution